FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk

Merck Animal Health gets FDA nod for groundbreaking dog allergy drug NUMELVI

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients

Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India

Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery

FDA greenlights Biocon’s Liraglutide for chronic weight management

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support